Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NestaCell · 1 trial · 1 indication
Ordinal scale (WHO ordinal scale that measures illness severity over time)
| Arm | Type | Description |
|---|---|---|
| NestaCell® | EXPERIMENTAL | A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects. |
| Name | Type | Description |
|---|---|---|
| NestaCell® | BIOLOGICAL | A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects. |
| Placebo | BIOLOGICAL | Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects. |
Inclusion Criteria: 1\. Male or female, aged ≥ 18 years 2. Present a confirmed or pending diagnosis of COVID-19, but with tomographic and clinical signs strongly suggestive of SARS-CoV-2 infection (COVID-19), with pulmonary impairment greater than or equal to 50% and: i. Oxygen saturation \<95%; ii...
NestaCell is an investigational monoclonal antibody being studied for the treatment of severe COVID-19 pneumonia. It is currently in Phase 2 clinical development and is not approved by the FDA. The drug is being evaluated in patients with severe COVID-19 pneumonia to assess its safety and efficacy.
NestaCell is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for its potential to treat severe COVID-19 pneumonia, though the exact mechanism of action is not publicly detailed.
NestaCell is being developed by Vera Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VERA. The company is conducting clinical research on NestaCell for the treatment of severe COVID-19 pneumonia.
NestaCell is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The Phase 2 trial for NestaCell in severe COVID-19 pneumonia has been completed, with results not yet reported.
NestaCell has one completed Phase 2 clinical trial, identified as NCT04315987, titled 'NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia.' The trial enrolled 90 participants in Brazil and was a randomized, double-blind, placebo-controlled study.
NestaCell is described as a monoclonal antibody, but the clinical trial title refers to it as a 'Mesenchymal Stem Cell' therapy. This suggests the drug may be a cell-based therapy, though the developer classifies it as a monoclonal antibody. The exact nature of NestaCell is not fully clarified.